Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Lee Harrison

Pittsburgh, PA Medical Doctor

NPI 1275507881 CMS profile 1290360

3601 5Th Ave, Falk Clinic, Suite 700, Pittsburgh, PA 15213

Open in the dashboard

General payments

$69,591

105 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Lee Harrison of Pittsburgh, PA is reported in the CMS Open Payments database as having received $69,591 across 105 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $10,444 13
2024 General $8,157 15
2023 General $4,443 11
2022 General $10,313 7
2020 General $1,273 5
2019 General $34,962 54

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lee Harrison
  • Pennsylvania median
  • Middle half of Pennsylvania
  • National median

In program year 2025, general payments to Lee Harrison were reported at $10,444. Among 44,217 Pennsylvania profiles paid that year, the median was $168 and the middle half received between $50 and $597.

Show as a table
Year Lee Harrison Pennsylvania median Middle half National median
2019 $34,962 $156 $46–$628 $163
2020 $1,273 $109 $33–$381 $114
2021 $0 $125 $35–$469 $132
2022 $10,313 $136 $40–$499 $149
2023 $4,443 $147 $46–$523 $160
2024 $8,157 $156 $46–$568 $164
2025 $10,444 $168 $50–$597 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Merck Sharp & Dohme Corporation $27,432 35 payments
  2. Pfizer Inc. $17,934 45 payments
  3. Pfizer International LLC $14,504 15 payments
  4. Seqirus USA Inc $6,499 3 payments
  5. GlaxoSmithKline, LLC. $2,860 6 payments
  6. Genzyme Corporation $362 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $55,174 66 payments
  2. Food and Beverage $7,717 34 payments
  3. Consulting Fee $5,010 1 payment
  4. Grant $800 1 payment
  5. Education $795 2 payments
  6. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $95 1 payment
Products named General payments · program years 2019–2025
  1. PNEUMOVAX 23 $10,552 13 payments
  2. PENBRAYA $7,058 14 payments
  3. PREVNAR 20 $2,724 6 payments
  4. PREVNAR - 13 $1,504 5 payments
  5. PREVNAR 13 $815 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 4 billing codes

Paid by Medicare

$3,029

Medicare's payments for the services billed

Medicare patients

18

Average age 68

Services billed

32

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 72%
Diabetes 61%
Chronic kidney disease 61%
Osteoporosis 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

105 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record